Humana Inc. (NYSE:HUM) Receives $225.48 Average Price Target from Brokerages

Shares of Humana Inc. (NYSE:HUM) have been given an average rating of “Hold” by the twenty-six ratings firms that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $225.4783.

A number of research firms recently commented on HUM. KeyCorp reiterated a “sector weight” rating on shares of Humana in a research note on Friday, December 12th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $344.00 target price on shares of Humana in a report on Tuesday, January 6th. Cantor Fitzgerald decreased their target price on Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a research report on Thursday, February 12th. Oppenheimer set a $250.00 price target on Humana in a report on Thursday, February 12th. Finally, UBS Group reissued a “neutral” rating on shares of Humana in a research report on Wednesday, February 25th.

Humana Trading Up 0.6%

HUM opened at $178.05 on Tuesday. Humana has a 12-month low of $163.11 and a 12-month high of $315.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00. The stock has a market capitalization of $21.38 billion, a PE ratio of 18.13, a P/E/G ratio of 1.89 and a beta of 0.44. The firm’s fifty day moving average price is $184.07 and its 200 day moving average price is $236.05.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping the consensus estimate of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the business earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, research analysts expect that Humana will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 27th. This represents a $3.54 annualized dividend and a yield of 2.0%. Humana’s payout ratio is presently 36.05%.

Insider Buying and Selling at Humana

In other Humana news, insider Sanjay K. Shetty bought 810 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were bought at an average cost of $185.21 per share, with a total value of $150,020.10. Following the completion of the acquisition, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently modified their holdings of HUM. Revolve Wealth Partners LLC bought a new position in shares of Humana during the fourth quarter valued at approximately $202,000. Woodline Partners LP raised its position in shares of Humana by 460.0% during the 1st quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock worth $2,697,000 after purchasing an additional 8,372 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Humana by 53.7% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after purchasing an additional 452 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Humana by 25.1% in the 2nd quarter. American Century Companies Inc. now owns 20,860 shares of the insurance provider’s stock worth $5,100,000 after purchasing an additional 4,184 shares during the last quarter. Finally, J.W. Cole Advisors Inc. boosted its position in Humana by 41.4% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 2,310 shares of the insurance provider’s stock valued at $565,000 after purchasing an additional 676 shares during the period. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.